Hyperthermia European Adjuvant Trial (HEAT)
A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)
Sponsor: Klinikum der Universitaet Muenchen, Grosshadern
A PHASE3 clinical study on Resected Pancreatic Adenocarcinoma, this trial is ongoing. The trial is conducted by Klinikum der Universitaet Muenchen, Grosshadern and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
May 2017 — Dec 2017 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Klinikum der Universitaet Muenchen, Grosshadern
- Ludwig-Maximilians - University of Munich
- The European Society for Hyperthermic Oncology
For direct contact, visit the study record on ClinicalTrials.gov .